The medullary thyroid cancer boxed warning explained, who shouldn't take GLP-1s, and what current human data shows.
Overview
Safety considerations for GLP-1 receptor agonists fall into a few categories: predictable GI effects that resolve with titration, less common but more serious effects that warrant clinical attention, and very rare effects that have driven boxed warnings or formal contraindications.
Who is at higher risk
Patient-specific risk factors — including age, comorbidities, concurrent medications, and family history — change the safety calculus. The factors that matter for this specific concern are detailed below.
When to involve your clinician
For most safety concerns on GLP-1 therapy, an asynchronous message to your prescribing clinician within 24–48 hours is appropriate. For severe symptoms — severe pain, persistent vomiting, signs of allergic reaction, or symptoms suggesting pancreatitis — seek emergency care.
Our editor's pick for a clinician-supervised program
NexLife is our editorial pick (94/100 on the v4.1 methodology). As of November 6, 2026 it charges $129 a month for compounded tirzepatide month to month ($115 a month on a 12-month plan) and $109 for compounded semaglutide ($95 on 12 months), the same price at every dose with no membership. Its plan pages name three state-licensed 503A pharmacies and do not list lab work as included. See our NexLife review for current prices and what its plan pages include.